If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
230
results.
Updated on
24/12/2025 [06:58:00]
Results 150 to 175 of 230
Absstract of: US2025375377A1
An opioid independent surgical anesthetic composition includes an injectable dosage form of a hydrogel having a plurality of solid lipid matrix particles entrapped therein. The solid lipid matrix particles include a lipophilic local anesthetic drug and a lipid glyceride (e.g., saturated triglyceride or lipid blend of various lipid glycerides). Methods for creating a long-acting local anesthetic product can include creating a bulk solid of a lipid matrix product by heating a lipid solvent above its melting point, dissolving a lipophilic local anesthetic drug therein, reducing a temperature of the resultant drug-lipid solution to below the melting point of the lipid solvent, and heat annealing the lipid matrix to remove or reduce presence of any unstable polymorphs in the lipid matrix. The methods can further include crushing the bulk solid of the lipid matrix product to form solid lipid matrix particles and entrapping the solid lipid matrix particles within a hydrogel.
Absstract of: US2025375391A1
The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.
Absstract of: US2025376534A1
Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
Absstract of: US2025375388A1
The present invention relates to nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
Absstract of: US2025375386A1
Provided herein are achromosomal dynamic active systems comprising a Type 1 pilus (TIP) and methods of making and using the same.
Absstract of: US2025375387A1
The present disclosure relates to nanoparticles containing cellular membrane and uses thereof. The nanoparticle comprises an interior compartment (or an inner core) and an outer surface (or shell) comprising a cellular membrane derived from a cell, said interior compartment (or an inner core) not providing a solid support to said cellular membrane in said outer surface (or shell). The present disclosure also relates to processes of making the nanoparticles. The present disclosure further relates to compositions comprising the nanoparticles and methods of using the nanoparticles.
Absstract of: US2025375390A1
The present invention provides lyophilised pharmaceutical compositions and methods of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising nucleic acid and lipid carrier particles and methods of making said lyophilised pharmaceutical compositions. The provided lyophilised compositions have improved critical quality attributes (CQAs) and the provided methods prevent the need for a deep-freeze cold chain. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.
Absstract of: US2025376686A1
A multi-functional near-infrared fluorescent polymer dot (Pdot)-siRNA nanoplatform is disclosed herein. The disclosed technology addresses challenges in siRNA delivery, including poor stability, degradation, and immune recognition, by utilizing positively charged Pdots synthesized from polymers, and electrostatic binding with negatively charged siRNA. The Pdots exhibit dual fluorescence emission at 588 nm and 775 nm, enabling real-time visualization of cellular uptake and siRNA delivery. The nanoplatform demonstrates efficient inhibition of target gene expression, and protein levels in cells. The Pdots provide minimal toxicity and persist in cells for extended periods, offering a robust tool for therapeutic applications, bioimaging, and molecular labeling. This approach combines siRNA delivery with simultaneous imaging, presenting a versatile method for targeted gene regulation and research applications.
Absstract of: WO2025252942A1
The invention relates to new calibrated-size gas-filled microvesicles bearing an overall negative charge, to their method of manufacturing and to their use. Said gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.20 or lower and a stabilizing envelope comprising a phospholipid selected from phosphatidic acid, phosphatidylserine or a mixture thereof and a pegylated phospholipid.
Absstract of: WO2025255027A1
The instant disclosure relates to lipid particles that harbor cationic lipids, the particles found to be capable of delivering associated cargoes - particularly nucleic acid cargoes when formulated as nucleic acid-lipid particles - intracellularly to skin tissue cells when administered topically to a subject. The instant disclosure provides compositions comprising such lipid particles, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and/or nucleic acid controller system), as well as methods and kits for delivering a lipid particle-associated therapeutic agent and/or for treating or preventing a disease or disorder, e.g., a skin disease or disorder, in a subject, using one or more lipid particle compositions provided herein.
Absstract of: WO2025254653A1
Particles are provided that include (a) a liposome having a negatively charged outer surface; (b) a first layer comprising poly-L-arginine (PLR), wherein the PLR is non-covalently associated with the negatively charged outer surface of the liposome; (c) a second layer, comprising hyaluronate (HA), wherein the HA is non-covalently associated with the first layer; and (d) a blood brain barrier-targeting peptide layer electrostatically coupled to the second layer; as are particles that are loaded with a therapeutic and their use for treating a brain cancer.
Absstract of: WO2025255534A1
Compounds are provided having the following structure: (I) or (II), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein X, 1r, 2r, 3r, R11, R12, R21, R22, R31 and R32 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Absstract of: WO2025254014A1
This preparation for delaying or preventing gingivitis and bone resorption associated with periodontal disease includes particles of a nano-sized or micro-sized biodegradable polymer containing a macrolide-based antimicrobial agent.
Absstract of: WO2025253270A1
An immunogenic composition that includes an adjuvant and a soluble protein. The adjuvant may be a nanoparticle, such as a zinc chitosan nanoparticle. The soluble protein may comprise a tag, such as a His tag. A method for inducing an immune response in a subject in need thereof, breaking an immune tolerance in a subject in need thereof, and/or for active immunization to prevent a disease in a subject by administering the immunogenic composition. A system for inducing an immune response in a subject in need thereof, breaking an immune tolerance in a subject in need thereof, and/or for active immunization to prevent a disease in a subject that includes the immunogenic composition and a delivery system.
Absstract of: WO2025254371A1
In some embodiments, a lipid compound has aliphatic chain-containing tail moieties that have an asymmetric structure. The lipid compound can be used as an ionizable lipid compound and stabilizes a pharmaceutically active substance, such as a nucleic acid-based therapeutic agent or vaccine. The expression efficiency of a target molecule encoded in a nucleic acid molecule is improved by using the ionizable lipid compound. The lipid compound can be applied to nucleic acid-based therapeutic agents or vaccines.
Absstract of: WO2025251519A1
The present invention relates to the field of nanomedicine. Disclosed are an intravenous oncolytic virus capable of enhancing the radiotherapy efficacy, and a preparation method therefor and a use thereof. In the present invention, PEI-Se-Se-PEG is used to modify the surface of a negatively charged oncolytic virus, thereby developing a "stealth" oncolytic virus suitable for intravenous injection, referred to as AD@PSSP. Compared with the prior art, intravenous injection of AD@PSSP can significantly prolong the circulation time of the oncolytic virus in blood and improve the safety; moreover, the inhibitory effect of radiotherapy on the growth of tumors of whole body is effectively improved, and long-lasting immunological memory can also be activated, thereby facilitating the inhibition of tumor recurrence.
Absstract of: WO2025251574A1
A cage-like nanocarrier for targeted delivery of siRNA, and a preparation method therefor and the use thereof. The preparation method comprises: (A) mutating a negatively charged or uncharged amino acid on the inner surface of a ferritin into a positively charged amino acid; and any one or more of the following steps: (B) coupling the N-terminus of the ferritin to a functional peptide having nucleic acid affinity; (C) coupling the N-terminus of the ferritin to a functional peptide promoting lysosomal escape; (D) truncating the E-helix at the C-terminus of the ferritin; (E) coupling the C-terminus of the ferritin to a functional peptide having nucleic acid affinity; and (F) coupling the C-terminus of the ferritin to a functional peptide promoting lysosomal escape. A new nucleic-acid-loaded protein nanocage carrier is constructed by means of modifying a negatively charged inner cavity of ferritin to make same positively charged. By means of electrostatic adsorption, a negatively charged siRNA can be efficiently loaded into a ferritin nanocage, thereby significantly improving the in-vivo and in-vitro delivery stability of siRNA, lysosomal escape functions, and efficacy of targeted therapy.
Absstract of: KR20250173666A
본 발명은 핵산 전달체에 관한 것으로서, 보다 상세하게는 다수의 핵산을 포함하는 핵산 코어 및 상기 핵산 코어의 표면을 코팅하는 지질 코팅층을 포함하고, 상기 지질 코팅층은 양이온성 지질, 중성 지질 및 PEG화 지질을 포함하는 핵산 코팅용 지질 조성물을 포함함으로써 상기 핵산을 세포에 전달할 때의 독성을 최소화할 수 있는 핵산 전달체에 관한 것이다.
Absstract of: US2024122864A1
The present invention provides compositions comprising biodegradable particles that encapsulate two or more epitopes linked together by one or more linkers that are susceptible to cleavage by specific proteases. The present invention further provides methods for inducing antigen-specific tolerance and protective immune responses and for the treatment inflammatory diseases, such as autoimmune diseases, allergies, cancers, or infectious diseases.
Absstract of: US2025361208A1
Provided herein are lipids having the Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Absstract of: JP2024009057A
To satisfy a need to develop novel means of extracting metals from the body, with the aim of preventing and/or treating pathologies related to dysregulation of metal homeostasis.SOLUTION: The present invention relates to the field of medical devices, more particularly to devices for extracting metals from an organism. The use of these devices makes it possible, for example, to prevent and/or treat pathologies linked to dysregulation of metal homeostasis in the organism, for example neurological diseases.SELECTED DRAWING: Figure 1
Absstract of: JP2025028132A
To provide prostacyclin compounds and compositions comprising the same.SOLUTION: Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.SELECTED DRAWING: None
Absstract of: CN120641085A
Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA) wherein the LNP comprises an ionizable lipid; a "helper" lipid, such as ceramide or distearoyl phosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid anchoring polymers; and uses thereof.
Absstract of: CN120641126A
Modified single-stranded DNA molecules, as well as methods of cell-free synthesis thereof and their use as therapeutic agents, are disclosed.
Nº publicación: JP2025540146A 11/12/2025
Applicant:
プロキューアールセラピューティクスツーベスローテンフェンノートシャップ
Absstract of: MX2025006656A
The invention relates to the field of diseases caused by high levels of LDL-C and/or fibrinogen, such as cardiovascular disease. The invention involves oligonucleotides for RNA editing technology in deaminating target adenosine nucleotides, such as the adenosine at position 1055, in transcripts of the human <i>B4GALT1 </i>gene.
BOPI
Electronic site
